semaglutide and type 2 diabetes Frontiers Semaglutide is a FDA-approved GLP-1

superbill available for reimbursement attempt

GLP-1 RA Maintenance Patient Education: Risks vs benefits were laid out regarding maintenance therapy given at lower than manufacturer recommendations (manufacture recommendations recommend keeping the patient on at max dose (Semaglutide 2.4 mg/100 units per week or Tirzepatide 15 mg/week)

This protocol was endorsed by an earlier Board

10.3390/nu10020226 61 DelcourtC.CristolJ.-P.TessierF.LgerC

In the Steimle study, the authors demonstrated the impact of ZIP8 and ZIP14 knockdown on Mn transport across the BBB by loading 54 Mn into either the apical or basolateral side of transwells (Steimle et al., 2019)

Palisade Bio plans to begin Phase Ib dosing for FSCD in the second half of 2025, with topline data expected in early 2026